SANGAMO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5178 USD | +2.94% |
|
+1.23% | -4.69% |
| Mar. 22 | Sangamo Therapeutics Prices $24 Million Registered Direct Offering | MT |
| Mar. 14 | Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 970.4 | 2,207 | 1,093 | 514.6 | 96.35 | 107.4 | - | - |
| Enterprise Value (EV) 1 | 958.6 | 1,566 | 627.8 | 207.1 | 15.35 | 148.2 | 236.6 | 308.8 |
| P/E ratio | -9.85 x | -17.3 x | -6.1 x | -2.51 x | -0.37 x | -1.04 x | -1.68 x | -1.36 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 9.47 x | 18.7 x | 9.87 x | 4.62 x | 0.55 x | 2.91 x | 1.68 x | 1.36 x |
| EV / Revenue | 9.36 x | 13.2 x | 5.67 x | 1.86 x | 0.09 x | 4.01 x | 3.69 x | 3.9 x |
| EV / EBITDA | -9.47 x | -12.6 x | -3.61 x | -1.09 x | -0.15 x | -1.37 x | -3.47 x | -7.41 x |
| EV / FCF | -5.8 x | 10.1 x | -2.45 x | -0.85 x | -0.06 x | -1.71 x | -3.98 x | -12.9 x |
| FCF Yield | -17.2% | 9.86% | -40.9% | -118% | -1,603% | -58.4% | -25.1% | -7.74% |
| Price to Book | 2.17 x | 4.21 x | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 115,938 | 141,441 | 145,675 | 163,880 | 177,347 | 207,496 | - | - |
| Reference price 2 | 8.370 | 15.60 | 7.500 | 3.140 | 0.5433 | 0.5178 | 0.5178 | 0.5178 |
| Announcement Date | 2/28/20 | 2/24/21 | 2/24/22 | 2/22/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 102.4 | 118.2 | 110.7 | 111.3 | 176.2 | 36.94 | 64.14 | 79.12 |
| EBITDA 1 | -101.2 | -123.9 | -173.9 | -189.2 | -103.9 | -107.9 | -68.2 | -41.7 |
| EBIT 1 | -105.2 | -129.6 | -183.3 | -201.3 | -274 | -116.6 | -91.57 | -99.67 |
| Operating Margin | -102.69% | -109.61% | -165.61% | -180.85% | -155.48% | -315.55% | -142.77% | -125.98% |
| Earnings before Tax (EBT) 1 | -95.42 | -120.8 | -178 | -191.8 | -262.9 | -109.1 | -86.76 | -91.85 |
| Net income 1 | -95.19 | -121 | -178.3 | -192.3 | -257.8 | -109.1 | -82.09 | -88.39 |
| Net margin | -92.93% | -102.37% | -161.05% | -172.76% | -146.3% | -295.21% | -127.99% | -111.72% |
| EPS 2 | -0.8500 | -0.9000 | -1.230 | -1.250 | -1.480 | -0.4988 | -0.3080 | -0.3814 |
| Free Cash Flow 1 | -165.3 | 154.5 | -256.5 | -243.8 | -246 | -86.5 | -59.4 | -23.9 |
| FCF margin | -161.42% | 130.68% | -231.73% | -219.05% | -139.59% | -234.14% | -92.62% | -30.21% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/20 | 2/24/21 | 2/24/22 | 2/22/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 28.56 | 27.99 | 28.23 | 29.38 | 26.46 | 27.23 | 158 | 6.835 | 9.398 | 2.042 | 6.361 | 7.718 | 7.157 | 17.39 | 12 |
| EBITDA 1 | -45.88 | -37.14 | -42.43 | -42.85 | -51.84 | -52.05 | 80.09 | -67.97 | -56.12 | -59.94 | -45.5 | -34.5 | -34.6 | 20.3 | - |
| EBIT 1 | -48.44 | -39.9 | -45.26 | -45.73 | -54.89 | -55.39 | 76.6 | -72.22 | -61.61 | -62.06 | -40.3 | -31.98 | -29.13 | -15.33 | -21 |
| Operating Margin | -169.58% | -142.57% | -160.32% | -155.67% | -207.46% | -203.42% | 48.5% | -1,056.69% | -655.55% | -3,039.13% | -633.49% | -414.41% | -406.94% | -88.17% | -175% |
| Earnings before Tax (EBT) 1 | -47.6 | -37.56 | -43.92 | -43.09 | -53.12 | -51.71 | 21.33 | -120.8 | -102.9 | -60.57 | -38.27 | -30.11 | -27.47 | -13.37 | -18 |
| Net income 1 | -47.69 | -37.5 | -43.98 | -43.17 | -53.16 | -51.97 | 21.13 | -114.5 | -104.2 | -60.3 | -38.27 | -30.11 | -27.47 | -13.37 | -18 |
| Net margin | -166.96% | -133.98% | -155.78% | -146.96% | -200.89% | -190.87% | 13.38% | -1,675.29% | -1,108.35% | -2,952.79% | -601.66% | -390.08% | -383.77% | -76.93% | -150% |
| EPS 2 | -0.3300 | -0.2600 | -0.3000 | -0.2900 | -0.3400 | -0.3200 | 0.1200 | -0.6600 | -0.5900 | -0.3400 | -0.2157 | -0.1500 | -0.1257 | -0.0671 | -0.0750 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/24/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/22/23 | 5/8/23 | 8/8/23 | 11/1/23 | 3/13/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 40.8 | 129 | 201 |
| Net Cash position 1 | 11.8 | 641 | 465 | 307 | 81 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.378 x | -1.894 x | -4.829 x |
| Free Cash Flow 1 | -165 | 154 | -257 | -244 | -246 | -86.5 | -59.4 | -23.9 |
| ROE (net income / shareholders' equity) | -23.8% | -26% | -40.8% | -57.4% | - | - | - | - |
| ROA (Net income/ Total Assets) | -15.5% | -15.4% | - | - | - | - | - | - |
| Assets 1 | 614 | 788 | - | - | - | - | - | - |
| Book Value Per Share | 3.860 | 3.710 | - | - | - | - | - | - |
| Cash Flow per Share | - | 1.260 | -1.610 | -1.450 | - | - | - | - |
| Capex 1 | 20.9 | 14.7 | 23.3 | 20.2 | 21.2 | 10 | 10 | 10 |
| Capex / Sales | 20.44% | 12.45% | 21.03% | 18.12% | 12% | 27.07% | 15.59% | 12.64% |
| Announcement Date | 2/28/20 | 2/24/21 | 2/24/22 | 2/22/23 | 3/13/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
0.5178
USD
Average target price
3.5
USD
Spread / Average Target
+575.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.69% | 107M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SGMO Stock
- Financials Sangamo Therapeutics, Inc.
